香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 自願公告 與聯合電子成立氮化鎵技術聯合實驗室 本公告由英諾賽科（蘇州）科技股份有限公司（「本公司」）自願作出，旨在使本公司 股東及潛在投資者了解本公司最新業務發展情況。 本公司宣佈，於2025年7月29日，本公司與全球領先的汽車電子系統供應商聯合 汽車電子有限公司（「聯合電子」）成立聯合實驗室，通過利用氮化鎵(GaN)器件在 高功率密度、低導通電阻、高轉換效率和更小的產品尺寸等方面的優勢，合作開 發先進的新能源汽車電力電子系統。 股東及潛在投資者於買賣本公司證券時，務請審慎行事。 承董事會命 英諾賽科（蘇州）科技股份有限公司 董事長兼執行董事 Weiwei Luo博士 中國，20 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 英諾賽科（ 蘇州）科技股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02577 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股 ...

InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 完成根據一般授權配售新H股 及 修訂《公司章程》 獨家整體協調人 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料 ...

Group 1: Economic Growth and Industrial Performance - Jiangsu province's industrial added value increased by 7.4% year-on-year in the first half of the year, with strategic emerging industries accounting for 42.1% of the total industrial output, up 0.5 percentage points from last year [1] - High-tech industries' output accounted for 51.8% of the province's total industrial output, reflecting a 0.4 percentage point increase from the first quarter [2] - Traditional industries remain significant, with manufacturing investment growing by 0.5%, particularly in automotive (21.6%), textiles (26.9%), and rubber and plastics (11.2%) [5] Group 2: Emerging Industries and Innovation - The number of high-tech enterprises in Jiangsu accounted for 36.3% of the province's industrial enterprises, generating 73.6% of the high-tech industry output [2] - Jiangsu is positioning itself as a leader in low-altitude economy, with over 30 companies in the drone manufacturing sector and a significant increase in drone take-off and landing sites [4] - The province has seen a surge in innovative pharmaceuticals, with 11 new drugs approved for market, ranking first in the country [8] Group 3: Technological Advancements and Digital Economy - Jiangsu has established 1,808 advanced intelligent factories, with significant growth in high-tech manufacturing and equipment manufacturing [7] - The province is actively exploring the integration of digital economy and traditional industries, with a 7.9% increase in the core digital economy industries' sales [9] - A total of 41 strategic emerging industry funds have been established, with a total scale exceeding 100 billion yuan, enhancing capital capabilities across the province [9][10]

Market Overview - The Hong Kong stock market showed volatility, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion HKD, with net inflows of 484 million HKD recorded in the Hong Kong Stock Connect [1] - The Hang Seng Index reached a high of 24,994.14 points, marking a 0.68% increase, with significant contributions from the technology sector [1][3] U.S. Market Performance - Investor optimism regarding corporate earnings outweighed concerns about trade developments, leading to gains in the U.S. stock market [2] - The S&P 500 Index closed at 6,305 points, up 0.1%, while the Nasdaq rose by 78 points or 0.4% to 20,974 points [2] - Notable stock movements included Alphabet rising by 2.8% ahead of its earnings report, while Tesla fell by 0.4% [2] Investment Opportunities - The report emphasizes the low valuation of Hong Kong stocks, inflows from mainland investors, and increased trading activity as positive indicators for the market's medium to long-term outlook [3] - Suggested sectors for investment include: 1. Technology sectors such as artificial intelligence, robotics, semiconductors, and industrial software [3] 2. Innovative pharmaceutical sectors supported by policy initiatives, along with traditional Chinese medicine and healthcare [3] 3. Coal, oil, gas, and telecommunications sectors benefiting from low-risk interest rates in mainland China [3] 4. Consumer sectors like clothing, footwear, and dining that are currently undervalued [3] Key Company Insights - The report highlights the performance of major companies, including: - China Railway Group, which is expected to see a decline in revenue and net profit for 2024, but has a strong order backlog providing future earnings support [10] - Alibaba's stock buyback and BYD's production milestone of 13 million electric vehicles are noted as significant developments [11] - The report suggests monitoring companies like China CRRC and Times Electric for their roles in the railway equipment manufacturing sector, which is poised for growth due to substantial infrastructure investments [9]

Core Viewpoint - InnoCare (stock code: 2577) announced a financing plan through the placement of new H shares, aiming to raise approximately HKD 550 million, with net proceeds expected to be around HKD 540 million after expenses [1] Group 1: Financing Details - The company plans to issue 13,584,000 new H shares at a placement price of HKD 40.50, representing a discount of about 8.9% compared to the previous trading day's closing price of HKD 44.45 [1] - The placement price also reflects a discount of approximately 3.0% compared to the average closing price over the last five trading days [1] - The new shares will account for approximately 1.54% of the existing issued share capital and about 1.52% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 270 million of the proceeds will be allocated for product upgrades and the development of new application technologies [1] - Around HKD 140 million will be used to repay existing interest-bearing bank debts [1] - Another HKD 140 million is designated for working capital and general operational purposes [1] Group 3: Completion Timeline - The issuance is expected to be completed on the first trading day after the fulfillment or waiver of placement conditions, but no later than five days after the placement agreement date or another date agreed upon in writing with the placement agent [1]

Core Viewpoint - InnoCare (02577.HK) has entered into a placement agreement to issue 13.584 million new H-shares at a price of HKD 40.50 per share, aiming to raise approximately HKD 550 million to enhance its financial strength and market competitiveness [1] Group 1: Placement Details - The placement shares represent about 2.77% of the total issued H-shares and approximately 1.54% of the total issued shares as of the announcement date [1] - The estimated total amount raised from the placement, assuming full subscription, is expected to be HKD 550 million, with a net amount of approximately HKD 544 million after deducting commissions and estimated expenses [1] Group 2: Use of Proceeds - Approximately 50% of the funds will be used to support product upgrades and technology research and development to enhance the competitiveness of GaN products [2] - About 25% of the funds will be allocated to repay existing interest-bearing bank debts, improving the company's financial condition and reducing financial expenses [2] - The remaining 25% will be used to supplement working capital and for general operational purposes, including talent recruitment and administrative expenses [2]

智通财经7月22日电，英诺赛科在港交所公告，拟配售13,584,000股新H股，配售价为每股40.50港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 根據一般授 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 變更聯席公司秘書 聯席公司秘書辭任 英諾賽科（蘇州）科技股份有限公司（「本公司」）董事會（「董事會」）近日收到劉麗 華女士的辭任申請，因工作變動原因，劉麗華女士辭去本公司之聯席公司秘書職 務，劉麗華女士之辭任自2025年7月18日（即取得香港聯合交易所有限公司（「香 港聯交所」）豁免公司秘書資格的批准之日）起生效。 劉麗華女士確認其與董事會之間並無意見分歧，亦無其他有關辭任之事宜需敦請 本公司股東加以垂注。劉麗華女士在擔任聯席公司秘書期間，勤勉盡責，恪盡職 守。董事會對劉麗華女士做出的重要貢獻表示衷心的感謝。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英諾賽科 ( 蘇 州 ) 科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 余先生及鍾先生的簡歷詳情如下： 余曉桐先生，1990年7月出生，中國籍。余先生現任本公 ...